LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 132

Search options

  1. Article: Head-to-Head Comparison of Tissue Factor-Dependent Procoagulant Potential of Small and Large Extracellular Vesicles in Healthy Subjects and in Patients with SARS-CoV-2 Infection.

    Brambilla, Marta / Frigerio, Roberto / Becchetti, Alessia / Gori, Alessandro / Cretich, Marina / Conti, Maria / Mazza, Antonella / Pengo, Martino / Camera, Marina

    Biology

    2023  Volume 12, Issue 9

    Abstract: The relative contribution of small (sEVs) and large extracellular vesicles (lEVs) to the total plasma procoagulant potential is not yet well defined. Thus, we compared total and ... ...

    Abstract The relative contribution of small (sEVs) and large extracellular vesicles (lEVs) to the total plasma procoagulant potential is not yet well defined. Thus, we compared total and TF
    Language English
    Publishing date 2023-09-13
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2661517-4
    ISSN 2079-7737
    ISSN 2079-7737
    DOI 10.3390/biology12091233
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Montelukast Inhibits Platelet Activation Induced by Plasma From COVID-19 Patients.

    Camera, Marina / Canzano, Paola / Brambilla, Marta / Rovati, G Enrico

    Frontiers in pharmacology

    2022  Volume 13, Page(s) 784214

    Abstract: Leukotrienes are important pro-inflammatory lipid mediators derived from the arachidonic acid metabolism. In particular, cysteinyl leukotrienes, namely ... ...

    Abstract Leukotrienes are important pro-inflammatory lipid mediators derived from the arachidonic acid metabolism. In particular, cysteinyl leukotrienes, namely LTC
    Language English
    Publishing date 2022-02-08
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2587355-6
    ISSN 1663-9812
    ISSN 1663-9812
    DOI 10.3389/fphar.2022.784214
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Letter by Brambilla et al Regarding Article, "Platelets Promote Thromboinflammation in SARS-CoV-2 Pneumonia".

    Brambilla, Marta / Canzano, Paola / Tremoli, Elena / Camera, Marina

    Arteriosclerosis, thrombosis, and vascular biology

    2021  Volume 41, Issue 3, Page(s) e183–e184

    MeSH term(s) Blood Platelets ; COVID-19 ; Humans ; Inflammation ; Pneumonia ; SARS-CoV-2 ; Thrombosis
    Language English
    Publishing date 2021-02-24
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 1221433-4
    ISSN 1524-4636 ; 1079-5642
    ISSN (online) 1524-4636
    ISSN 1079-5642
    DOI 10.1161/ATVBAHA.120.315867
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1705: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Letter by Brambilla et al Regarding Article, "Patients With COVID-19 Have Elevated Levels of Circulating Extracellular Vesicle Tissue Factor Activity That Is Associated With Severity and Mortality-Brief Report".

    Brambilla, Marta / Canzano, Paola / Becchetti, Alessia / Tremoli, Elena / Camera, Marina

    Arteriosclerosis, thrombosis, and vascular biology

    2021  Volume 41, Issue 6, Page(s) e379–e380

    MeSH term(s) COVID-19 ; Extracellular Vesicles ; Humans ; SARS-CoV-2 ; Thromboplastin
    Chemical Substances Thromboplastin (9035-58-9)
    Language English
    Publishing date 2021-05-26
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 1221433-4
    ISSN 1524-4636 ; 1079-5642
    ISSN (online) 1524-4636
    ISSN 1079-5642
    DOI 10.1161/ATVBAHA.121.316188
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1705: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Head-to-Head Comparison of Tissue Factor-Dependent Procoagulant Potential of Small and Large Extracellular Vesicles in Healthy Subjects and in Patients with SARS-CoV-2 Infection

    Marta Brambilla / Roberto Frigerio / Alessia Becchetti / Alessandro Gori / Marina Cretich / Maria Conti / Antonella Mazza / Martino Pengo / Marina Camera

    Biology, Vol 12, Iss 1233, p

    2023  Volume 1233

    Abstract: The relative contribution of small (sEVs) and large extracellular vesicles (lEVs) to the total plasma procoagulant potential is not yet well defined. Thus, we compared total and TF pos -sEVs and -lEVs isolated from healthy subjects and COVID-19 patients ... ...

    Abstract The relative contribution of small (sEVs) and large extracellular vesicles (lEVs) to the total plasma procoagulant potential is not yet well defined. Thus, we compared total and TF pos -sEVs and -lEVs isolated from healthy subjects and COVID-19 patients during the acute phase of the infection and after symptom remission in terms of (1) vesicle enumeration using nanoparticle tracking assay, imaging flow cytometry, and TF immunofluorescence localization in a single-vesicle analysis using microarrays; (2) cellular origin; and (3) TF-dependent Xa generation capacity, as well as assessing the contribution of the TF inhibitor, TFPI. In healthy subjects, the plasma concentration of CD9/CD63/CD81 pos sEVs was 30 times greater than that of calcein pos lEVs, and both were mainly released by platelets. Compared to lEVs, the levels of TF pos -sEVs were 2-fold higher. The TF-dependent Xa generation capacity of lEVs was three times greater than that of sEVs, with the latter being hindered by TFPI. Compared to HSs, the amounts of total and TF pos -sEVs and -lEVs were significantly greater in acute COVID-19 patients, which reverted to the physiological values at the 6-month follow-up. Interestingly, the FXa generation of lEVs only significantly increased during acute infection, with that of sEV being similar to that of HSs. Thus, in both healthy subjects and COVID-19 patients, the TF-dependent procoagulant potential is mostly sustained by large vesicles.
    Keywords small extracellular vesicles ; large extracellular vesicles ; tissue factor ; factor Xa generation ; COVID-19 ; Biology (General) ; QH301-705.5
    Subject code 333
    Language English
    Publishing date 2023-09-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  6. Article ; Online: Alterations in platelets during SARS-CoV-2 infection.

    Brambilla, Marta / Canzano, Paola / Becchetti, Alessia / Tremoli, Elena / Camera, Marina

    Platelets

    2021  Volume 33, Issue 2, Page(s) 192–199

    Abstract: Coronavirus disease 2019 (COVID-19) is a pandemic syndrome caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. SARS-CoV-2 infection induces a process of inflammation and thrombosis supported by an altered platelet activation ...

    Abstract Coronavirus disease 2019 (COVID-19) is a pandemic syndrome caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. SARS-CoV-2 infection induces a process of inflammation and thrombosis supported by an altered platelet activation state. This platelet activation is peculiar being characterized by the formation of platelet-leukocytes rather than platelet-platelet aggregates and by an increased procoagulant potential supported by elevated levels of TF positive platelets and microvesicles.Therapeutic strategies targeting, beyond systemic inflammation (i.e. with tocilizumab, an anti interleukin-6 receptor), this state of platelet activation might therefore be beneficial. Among the antithrombotic drugs proposed as candidates to treat patients with SARS-CoV-2 infection, antiplatelet drugs, such as aspirin are showing promising results.
    MeSH term(s) Blood Platelets/metabolism ; COVID-19/blood ; Humans ; SARS-CoV-2
    Language English
    Publishing date 2021-08-13
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 1034283-7
    ISSN 1369-1635 ; 0953-7104
    ISSN (online) 1369-1635
    ISSN 0953-7104
    DOI 10.1080/09537104.2021.1962519
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2888: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Drug repurposing in cardiovascular diseases: Opportunity or hopeless dream?

    Gelosa, Paolo / Castiglioni, Laura / Camera, Marina / Sironi, Luigi

    Biochemical pharmacology

    2020  Volume 177, Page(s) 113894

    Abstract: Cardiovascular disease remains - despite the development of new drugs, devices, and therapeutic strategies - the leading cause of death and disability worldwide. There is therefore a great need to implement the pharmacological armamentarium, considering ... ...

    Abstract Cardiovascular disease remains - despite the development of new drugs, devices, and therapeutic strategies - the leading cause of death and disability worldwide. There is therefore a great need to implement the pharmacological armamentarium, considering also the need to balance the therapeutic and the side effects. Furthermore, the best choice among the drug treatment options and reduction of side effects remain urgent problems for studies of cardiovascular disease. In this context, drug repurposing could be an innovative way and opportunity to extend and improve pharmacological tools. Indeed, applying well-established drugs and compounds to new indications, drug repurposing has already been proven efficient and safe in humans. Furthermore, this approach generates lower costs and needs shorter time for approval than the development of a de novo drug. In the current review, we discuss the main evidence for the repurposing in cardiovascular diseases of drugs approved and marketed for other pathologies by reviewing their mechanisms of action and the results reported in observational and then in randomized studies.
    MeSH term(s) Antibodies, Monoclonal/pharmacology ; Antibodies, Monoclonal/therapeutic use ; Cardiovascular Diseases/drug therapy ; Cholinesterase Inhibitors/therapeutic use ; Colchicine/therapeutic use ; Cytokines/antagonists & inhibitors ; Drug Repositioning/methods ; Glucagon-Like Peptide-1 Receptor/agonists ; Humans ; Interleukin 1 Receptor Antagonist Protein/pharmacology ; Interleukin 1 Receptor Antagonist Protein/therapeutic use ; Metformin/therapeutic use ; Methotrexate/therapeutic use ; Phosphodiesterase 5 Inhibitors/therapeutic use ; Xanthine Oxidase/antagonists & inhibitors
    Chemical Substances Antibodies, Monoclonal ; Cholinesterase Inhibitors ; Cytokines ; Glucagon-Like Peptide-1 Receptor ; Interleukin 1 Receptor Antagonist Protein ; Phosphodiesterase 5 Inhibitors ; Metformin (9100L32L2N) ; Xanthine Oxidase (EC 1.17.3.2) ; Colchicine (SML2Y3J35T) ; Methotrexate (YL5FZ2Y5U1)
    Language English
    Publishing date 2020-03-03
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 208787-x
    ISSN 1873-2968 ; 0006-2952
    ISSN (online) 1873-2968
    ISSN 0006-2952
    DOI 10.1016/j.bcp.2020.113894
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 19: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Repurposing of drugs approved for cardiovascular diseases: Opportunity or mirage?

    Gelosa, Paolo / Castiglioni, Laura / Camera, Marina / Sironi, Luigi

    Biochemical pharmacology

    2020  Volume 177, Page(s) 113895

    Abstract: Drug repurposing is a promising way in drug discovery to identify new therapeutic uses -different from the original medical indication- for existing drugs. It has many advantages over traditional approaches to de novo drug discovery, since it can ... ...

    Abstract Drug repurposing is a promising way in drug discovery to identify new therapeutic uses -different from the original medical indication- for existing drugs. It has many advantages over traditional approaches to de novo drug discovery, since it can significantly reduce healthcare costs and development timeline. In this review, we discuss the possible repurposing of drugs approved for cardiovascular diseases, such as β-blockers, angiotensin converting enzyme inhibitors (ACE-Is), angiotensin II receptor blockers (ARBs), statins, aspirin, cardiac glycosides and low-molecular-weight heparins (LMWHs). Indeed, numerous experimental and epidemiological studies have reported promising anti-cancer activities for these drugs. It is worth mentioning, however, that the results of these studies are often controversial and very few data were obtained by controlled prospective clinical trials. Therefore, no final conclusion has yet been reached in this area and no final recommendations can be made. Moreover, β-blockers, ARBs and statins showed promising results in randomised controlled trials (RCTs) where pathological conditions other than cancer were considered. The results obtained have led or may lead to new indications for these drugs. For each drug or class of drugs, the potential molecular mechanisms of action justifying repurposing, results obtained in vitro and in animal models and data from epidemiological and randomized studies are described.
    MeSH term(s) Acute Kidney Injury/drug therapy ; Adrenergic beta-Antagonists/therapeutic use ; Angiotensin Receptor Antagonists/therapeutic use ; Angiotensin-Converting Enzyme Inhibitors/therapeutic use ; Animals ; Aspirin/therapeutic use ; Bacterial Infections/drug therapy ; Cardiac Glycosides/therapeutic use ; Cardiovascular Diseases/drug therapy ; Drug Repositioning/methods ; Heparin, Low-Molecular-Weight/therapeutic use ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use ; Marfan Syndrome/drug therapy ; Migraine Disorders/drug therapy ; Mycoses/drug therapy ; Neoplasms/drug therapy ; Periodontitis/drug therapy
    Chemical Substances Adrenergic beta-Antagonists ; Angiotensin Receptor Antagonists ; Angiotensin-Converting Enzyme Inhibitors ; Cardiac Glycosides ; Heparin, Low-Molecular-Weight ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Aspirin (R16CO5Y76E)
    Language English
    Publishing date 2020-03-04
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 208787-x
    ISSN 1873-2968 ; 0006-2952
    ISSN (online) 1873-2968
    ISSN 0006-2952
    DOI 10.1016/j.bcp.2020.113895
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 19: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article: Extracellular Vesicles in Pulmonary Hypertension: A Dangerous Liaison?

    Conti, Maria / Minniti, Marianna / Tiné, Mariaenrica / De Francesco, Miriam / Gaeta, Roberta / Nieri, Dario / Semenzato, Umberto / Biondini, Davide / Camera, Marina / Cosio, Manuel G / Saetta, Marina / Celi, Alessandro / Bazzan, Erica / Neri, Tommaso

    Biology

    2023  Volume 12, Issue 8

    Abstract: The term pulmonary hypertension (PH) refers to different conditions, all characterized by increased pressure and resistance in the pulmonary arterial bed. PH has a wide range of causes (essentially, cardiovascular, pulmonary, or connective tissue ... ...

    Abstract The term pulmonary hypertension (PH) refers to different conditions, all characterized by increased pressure and resistance in the pulmonary arterial bed. PH has a wide range of causes (essentially, cardiovascular, pulmonary, or connective tissue disorders); however, idiopathic (i.e., without a clear cause) PH exists. This chronic, progressive, and sometimes devastating disease can finally lead to right heart failure and eventually death, through pulmonary vascular remodeling and dysfunction. The exact nature of PH pathophysiology is sometimes still unclear. Extracellular vesicles (EVs), previously known as apoptotic bodies, microvesicles, and exosomes, are small membrane-bound vesicles that are generated by almost all cell types and can be detected in a variety of physiological fluids. EVs are involved in intercellular communication, thus influencing immunological response, inflammation, embryogenesis, aging, and regenerative processes. Indeed, they transport chemokines, cytokines, lipids, RNA and miRNA, and other biologically active molecules. Although the precise functions of EVs are still not fully known, there is mounting evidence that they can play a significant role in the pathophysiology of PH. In this review, after briefly recapping the key stages of PH pathogenesis, we discuss the current evidence on the functions of EVs both as PH biomarkers and potential participants in the distinct pathways of disease progression.
    Language English
    Publishing date 2023-08-07
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2661517-4
    ISSN 2079-7737
    ISSN 2079-7737
    DOI 10.3390/biology12081099
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article: Perioperative Complications after Hip and Knee Revision Arthroplasty in the over 80 Years Old Population: A Retrospective Observational Case-Control Study.

    Di Matteo, Vincenzo / Di Pilla, Marina / La Camera, Francesco / Morenghi, Emanuela / Grappiolo, Guido / Loppini, Mattia

    Journal of clinical medicine

    2023  Volume 12, Issue 6

    Abstract: Background: The number of joint revision arthroplasties has increased in the elderly population, which is burdened by several perioperative risks.: Methods: Patients who underwent hip and knee revision arthroplasty were retrospectively included, and ... ...

    Abstract Background: The number of joint revision arthroplasties has increased in the elderly population, which is burdened by several perioperative risks.
    Methods: Patients who underwent hip and knee revision arthroplasty were retrospectively included, and they were divided into two groups by age: <80 years old (Group 1) and ≥80 years old (Group 2). The primary outcome was to compare perioperative complication rates. The secondary outcome was to compare the 30-day, 90-day, and 1-year readmission rates.
    Results: In total, 74 patients in Group 1 and 75 patients in Group 2 were included. Postoperative anemia affected 13 patients in Group 1 (17.6%) and 25 in Group 2 (33.3%,
    Conclusion: The revision arthroplasty procedure in patients over 80 years old is not associated with a higher risk of perioperative complications, or higher readmission rate compared with younger patients undergoing hip and knee revision surgery.
    Language English
    Publishing date 2023-03-11
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2662592-1
    ISSN 2077-0383
    ISSN 2077-0383
    DOI 10.3390/jcm12062186
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top